

- fetal development of, 1520
 functional assessment of, 265e-9-10, 265e-10f
 metabolism in, 265e-10-11
 physical examination of, 1447-1448. *See also*
 Heart murmurs; Heart sounds
 regenerative potential of, 265e-12
 tissue engineering strategies, 92e-2, 92e-3v
- Heart block. *See* Atrioventricular (AV)
 conduction block
- Heartburn, 261, 262, 1876, 1900. *See also*
 Gastroesophageal reflux disease
 (GERD); Indigestion
- Heart disease. *See* Cardiovascular disease
- Heart failure (HF), **1500**, **1507**
 anemia in, 1514
 atrial arrhythmias in, 1514
 cardiac cirrhosis in, 2062
 cardiogenic shock in. *See* Cardiogenic shock
 in chronic kidney disease, 1817
 clinical features of
 cerebral, 1504
 Cheyne-Stokes respiration, 1503-1504
 dyspnea, 47e-3, 1503, 1661
 edema, 251-252, 253
 fatigue, 152, 1503
 gastrointestinal, 1504
 hemoptysis, 246
 hypokalemia, 307
 hyponatremia, 299, 302
 hypoxia, 248
 orthopnea, 1503
 paroxysmal nocturnal dyspnea, 1503-1504
 pleural effusion, 1716-1717
 splenomegaly, 411
 definition of, 1500
 depression in, 1514
 diagnosis of, 1504-1505
 biomarkers, 1505
 chest radiograph, 308e-7f, 1505
 echocardiography, 1505
 laboratory tests, 1504-1505
 left ventricular function, 1505
 in new-onset disease, 270e-20-21, 270e-21f,
 270e-22f, 270e-27v
 stress testing, 1505
 differential diagnosis of, 1505
 effect on drug concentration and response, 37
 epidemiology of, 15, 1500-1501
 etiology of, 1501, 1501t
 folate deficiency in, 647
 frailty and, 77
 functional classification of, 1439-1440, 1440t,
 1501, 1501t, 1581t
 global considerations in, 15, 1500-1501
 hypertension and, 1615, 1625
 in infective endocarditis, 818, 825
 in ischemic heart disease, 1579, 1590
 mitral regurgitation in, 1515
 myocardial infarction and, 1607-1608
 pathogenesis of
 depressed ejection fraction, 1501-1503,
 1501t, 1502f
 left ventricular remodeling, 1502-1503,
 1503t
 preserved ejection fraction, 1501, 1501t,
 1508f
 physical examination in, 1504
 prognosis of, 1501
 in rheumatic fever, 2153
 sleep-disordered breathing in, 1514
 sudden cardiac death in, 1514
 treatment of
 in acute decompensated disease, **1507**
 inotropic therapy, 1509-1510, 1510t
 neurohormonal antagonists, 1510
 principles of, 1507-1508, 1509f
 vascular therapy, 1509, 1510t
 volume management, 1508-1509, 1510t
 in association with STEMI, 1578
 cardiac resynchronization therapy, 1514
 cardiac transplantation. *See* Cardiac
 transplantation
 cellular and gene-based, 1515
 comorbidity management, 1514
 global considerations in, 1516
 implantable cardiac defibrillator, 1514,
 1515t, 1770
 with preserved ejection fraction, 1507,
 1508f
 racial/ethnic disparities in, 16e-1
 with reduced ejection fraction, **1510**
 anticoagulants and antiplatelets, 1513
 ARBs, 1511-1512
 arteriovenous vasodilators, 1512
 calcium channel antagonists, 1513
 digoxin, 1512
 diuretics, 1512-1513
 enhanced external counterpulsation,
 1513
 exercise, 1513
 fish oil, 1513
 heart rate modification, 1512
 inflammation, 1513
 micronutrients, 1513
 neurohormonal antagonists, 1511
 novel neurohormonal antagonists, 1513
 principles of, 1510-1511, 1511f
 statins, 1513
 sleep disordered-breathing, 1514
 specialized nutritional support, 98e-4
 supportive care, 1515-1516
 surgical, 1514-1515
 ventricular assist devices, 1518-1519, 1519f
- Heartland virus, 1309t
- HeartMate II LVAD, 1518, 1519f
- Heart murmurs
 in aortic regurgitation, 51e-1, 51e-1f, 51e-7,
 1448f, 1449, 1536
 in aortic root-to-right-heart shunts, 1523
 in aortic stenosis, 51e-1, 51e-2f, 51e-3, 51e-7,
 1448, 1448f, 1531
 approach to the patient, **51e-1**, 1441, 1441f
 in atrial septal defect, 51e-1, 51e-3-4, 51e-6,
 1448, 1521
 auscultation of, 51e-6-8, 51e-7f, 51e-7t,
 1448-1449, 1448f
 benign, 1449
 character of, 51e-1
 clinical context of, 51e-8
 continuous, 51e-1f, 51e-2t, 51e-6, 51e-7f,
 1449
 diastolic, 51e-1f, 51e-2t, 51e-5-6, 51e-6f,
 1449
 duration of, 51e-1
 dynamic evaluation of, 51e-6-8, 51e-6f,
 1449-1450, 1450t
 echocardiography in, 51e-8, 1440
 etiology of, 51e-1, 51e-2t
 in hypertrophic cardiomyopathy, 1448, 1569
 in infective endocarditis, 818
 intensity of, 51e-2, 1450, 1450t
 location and radiation of, 51e-1-2, 51e-2f
 in mitral regurgitation, 51e-1-5, 51e-1f,
 51e-2f, 1448, 1448f, 1545
 in mitral stenosis, 51e-1, 51e-1f, 51e-6, 51e-6f,
 1448f, 1449, 1540
 in mitral valve prolapse, 51e-2, 51e-3, 51e-3f,
 51e-4, 51e-7, 1449, 1449f, 1546
 in patent ductus arteriosus, 51e-2f, 1449
 in prosthetic valves, 1450
 in pulmonic regurgitation, 51e-5-6, 1449,
 1550
 in pulmonic stenosis, 51e-1f, 51e-2f, 51e-3,
 51e-4f, 1448, 1525
 systolic, 51e-1f, 51e-2-5, 51e-2t
 early, 51e-2-3
 holosystolic, 51e-1f, 51e-4-5, 51e-5f
 late, 51e-4
 mid-systolic, 51e-3-4, 51e-3f
 in tricuspid regurgitation, 1448, 1548
 in tricuspid stenosis, 51e-1f, 1449, 1547
 in ventricular septal defect, 51e-1f, 51e-2-5,
 51e-2f, 1449
- Heart rate
 deep breathing and, 2640, 2641t
 intrinsic, 1468
 in pregnancy, 45
 resting, 1468
 in shock, 1730t
 during sleep, 187
 Valsalva maneuver and, 2640, 2640t
- HEART score, 102f
- Heart sounds. *See also* Heart murmurs
 in aortic regurgitation, 1536
 in aortic stenosis, 1531
 in atrial septal defect, 1446f, 1447, 1521
 diastolic, 1447-1448
 in heart failure, 1504
 in hypertension, 1622
 in ischemic heart disease, 1581-1582
 in mitral regurgitation, 1545
 in mitral stenosis, 1540
 in mitral valve prolapse, 1546
 in myocardial infarction, 1600
 in myxoma, 51e-6, 289e-1
 normal, 1446f, 1447
 in pericardial disease, 1450
 in prosthetic valves, 1450
 in pulmonary hypertension, 1655
 in pulmonic stenosis, 1525
 second, splitting of, 51e-7, 51e-7f, 1446f, 1447
 systolic, 1447
 in tricuspid regurgitation, 1548
 in tricuspid stenosis, 1547
- Heart transplantation. *See* Cardiac
 transplantation
- HeartWare Ventricular Assist System, 1519
- Heartworm, 1423
- Heat conservation, 124
- Heat cramps, 479e-2
- Heat edema, 479e-1
- Heat exhaustion, 479e-2
- Heat-labile enterotoxin, *E. coli*, 853
- Heat loss, 124, 478e-1
- Heat production, 124
- Heat-related illness, **479e-1**
 cooling strategies for, 479e-3
 differential diagnosis of, 124, 479e-1, 479e-2t
 heat cramps, 479e-2
 heat exhaustion, 479e-2
 heatstroke, 124, 479e-2-3, 479e-3t
 minor syndromes of, 479e-1
 prognosis of, 479e-4
 resuscitation in, 479e-3-4
 risk factors for, 479e-1, 479e-2t
- Heat sensitivity, in MS, 2663
- Heat shock protein, 372e-24t
- Heat stability test, hemoglobin, 637
- Heat-stable enterotoxin, *E. coli*, 853
- Heatstroke, 124, 479e-2-3, 479e-3t
- Heat syncope, 479e-1
- Heat therapy, for dysmenorrhea, 338
- Heat waves, 151e-2
- Heavy breathing, 47e-1t
- Heavy chain diseases, 718-719
- Heavy metal pigmentation, 240t, 361
- Heavy metal poisoning, **472e-1**, 1862. *See also*
specific metals
- Heberden's nodes, 2226f
- Hedgehog pathway, 387, 500, 500f
- Heel
 bursitis of, 2247
 plantar fasciitis of, 2249-2250
- Heel-knee-shin maneuver, 2539
- Heimlich maneuver, 1768
- Heinz bodies
 after splenectomy, 413
 in G6PD deficiency, 655
 laboratory identification of, 81e-1, 81e-5f
 in sickle cell syndromes, 636
 in splenomegaly, 410
 unstable hemoglobin variants and, 637
- HELEX septal occluder, 297e-7f
- Helicobacter cinaedi* infection, 1059, 1059t
- Helicobacter fennelliae* infection, 1059, 1059t
- Helicobacter pylori*, 1038-1039, 1915
- Helicobacter pylori* infections
 antibiotic resistance in, 934
 breath odor in, 242
 clinical features of, 1039-1040
 diagnosis of, 262, 1040, 1040t, 1919, 1920t
 epidemiology of, 1038, 1915